July - September 2010

September 30, 2010		Takeda Announces Changes in Management of Pharmaceutical Research Division
September 28, 2010		Takeda Debuts on the Dow Jones Sustainability Asia Pacific Index
September 22, 2010		PATIENTS LIVING WITH GERD NOW HAVE A NEW TREATMENT OPTION FOR IMPROVED AND SUSTAINED SYMPTOM RELIEF
September 17, 2010		Takeda to Construct New Manufacturing Facilities for Pharmaceutical Products within its Hikari Plant Premise in Japan
September 2, 2010		Orexigen® Therapeutics and Takeda Enter into Partnership to Commercialize Contrave® in North America
August 31, 2010		Takeda Announces New Initiative in Cell Culture-Based Influenza Vaccines
August 20, 2010		Approval of Additional Indication of NESINA®: Combination Therapy with Thiazolidinediones for Type 2 Diabetes in Japan
August 20, 2010		Approval of an Additional Indication of"Takepron® Capsules 15" and "Takepron® OD Tablets 15" for Prevention of Recurrence of NSAIDs-Associated Gastric Ulcer/Duodenal Ulcer in Japan
August 5, 2010		AFFYMAX AND TAKEDA ANNOUNCE PRELIMINARY U.S. REGISTRATION STRATEGY FOR INVESTIGATIONAL DRUG, HEMATIDE™/PEGINESATIDE, TO TREAT ANEMIA IN CHRONIC RENAL FAILURE
July 30, 2010		Takeda Announces the Appointment of Executive Vice President, International Operations (Americas/Europe) and Senior Vice President, International Operations (Asia), the establishment of new organization
July 30, 2010		Takeda Expands International Operations Leadership
July 23, 2010		Approval of an Additional Indication of "Takepron® Capsules 15" and "Takepron® OD Tablets 15" in Japan for Prevention of Recurrence of Gastric Ulcer or Duodenal Ulcer during Low-dose Aspirin Administration
July 16, 2010		Approval of Lampion® Pack in Japan for Secondary Eradication of Helicobacter pylori
July 12, 2010		Notice Concerning the Determination of the Items of Stock Options (Stock Acquisition Rights) for Members of the Board of Directors
July 9, 2010		Takeda Included in the FTSE4Good Global Index for the Sixth Consecutive Year
July 6, 2010		Launches of "ROZEREM®" for treatment of insomnia, "METACT®" for treatment of type 2 diabetes and Actos® Orally Disintegrating Tablets for treatment of type 2 diabetes in Japan